1. Home
  2. GLTO vs DGLY Comparison

GLTO vs DGLY Comparison

Compare GLTO & DGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLTO
  • DGLY
  • Stock Information
  • Founded
  • GLTO 2011
  • DGLY N/A
  • Country
  • GLTO Denmark
  • DGLY United States
  • Employees
  • GLTO N/A
  • DGLY N/A
  • Industry
  • GLTO Biotechnology: Pharmaceutical Preparations
  • DGLY Radio And Television Broadcasting And Communications Equipment
  • Sector
  • GLTO Health Care
  • DGLY Technology
  • Exchange
  • GLTO Nasdaq
  • DGLY Nasdaq
  • Market Cap
  • GLTO 4.5M
  • DGLY 4.1M
  • IPO Year
  • GLTO 2020
  • DGLY N/A
  • Fundamental
  • Price
  • GLTO $3.54
  • DGLY $2.26
  • Analyst Decision
  • GLTO Buy
  • DGLY
  • Analyst Count
  • GLTO 1
  • DGLY 0
  • Target Price
  • GLTO $10.00
  • DGLY N/A
  • AVG Volume (30 Days)
  • GLTO 13.7K
  • DGLY 115.1K
  • Earning Date
  • GLTO 08-11-2025
  • DGLY 08-15-2025
  • Dividend Yield
  • GLTO N/A
  • DGLY N/A
  • EPS Growth
  • GLTO N/A
  • DGLY N/A
  • EPS
  • GLTO N/A
  • DGLY N/A
  • Revenue
  • GLTO N/A
  • DGLY $18,596,715.00
  • Revenue This Year
  • GLTO N/A
  • DGLY N/A
  • Revenue Next Year
  • GLTO N/A
  • DGLY N/A
  • P/E Ratio
  • GLTO N/A
  • DGLY N/A
  • Revenue Growth
  • GLTO N/A
  • DGLY N/A
  • 52 Week Low
  • GLTO $2.01
  • DGLY $1.93
  • 52 Week High
  • GLTO $16.07
  • DGLY $265.00
  • Technical
  • Relative Strength Index (RSI)
  • GLTO 59.96
  • DGLY 25.38
  • Support Level
  • GLTO $3.24
  • DGLY $2.17
  • Resistance Level
  • GLTO $3.60
  • DGLY $2.32
  • Average True Range (ATR)
  • GLTO 0.26
  • DGLY 0.15
  • MACD
  • GLTO -0.01
  • DGLY 1.10
  • Stochastic Oscillator
  • GLTO 60.98
  • DGLY 20.93

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

About DGLY Digital Ally Inc.

Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.

Share on Social Networks: